Also known as: Ozurdex, steroids
Dexamethasone is a fluorinated glucocorticoid used broadly for anti-inflammatory and immunosuppressive purposes across rheumatic, allergic, pulmonary, neurologic, oncologic, and endocrine indications. It is available in multiple administration routes including oral, injectable, ophthalmic, and topical forms. It is an established generic essential medicine.
FDA approved subcutaneous isatuximab-irfc for multiple myeloma. Phase 3 EMN24 trial showed 77% MRD negativity with Isa-KRd quadruplet therapy. Phase 2 study showed 77% hematologic response rate in relapsed/refractory AL amyloidosis.
A Cleveland Clinic study found no racial survival disparities in multiple myeloma when patients have equal access to modern therapies. Clinical cases demonstrate long-term remission with second stem cell transplants and targeted agents like daratumumab.
The FDA has accepted an NDA for iberdomide in combination with anti-CD38 antibodies for relapsed or refractory multiple myeloma. A phase 2 study reports a 39% near complete response rate for the DaraKPd quadruplet therapy with durable MRD negativity. Preclinical research shows the RXR agonist IRX4204 sensitizes myeloma cells to ferroptosis and enhances lenalidomide efficacy.
BMS's mezigdomide doubled progression-free survival in relapsed/refractory multiple myeloma at ASCO, while the FDA reviews iberdomide with a decision due by August 17. C4 Therapeutics has dosed the first patient in its Phase 2 MOMENTUM trial of cemsidomide.
An interim phase 3 analysis showed mezigdomide plus carfilzomib and dexamethasone reduced the risk of progression or death in relapsed/refractory multiple myeloma. The SUCCESSOR-2 study remains ongoing and will assess overall survival and safety.
Phase 3 trial data show daratumumab reduced relapse risk by 74% in NMOSD. Separately, the FDA accepted an NDA for iberdomide plus daratumumab/dexamethasone in relapsed/refractory multiple myeloma, with a PDUFA date of August 17, 2026.
ALX Oncology has multiple 2026 catalysts for Evorpacept and ALX2004. Interim ASPEN-09 data are expected in Q3 2026, while an initial safety update from the phase 1 ALX2004 trial is expected in 1H 2026.
Researchers have engineered immune cells to sense cancer metabolites, improving tumor infiltration in solid cancers. Separate studies identify Kappa and Lambda Myeloma Antigens as specific targets for multiple myeloma treatment, while mRNA-based personalized cancer vaccines show promise through AI-driven neoantigen selection.
A clinical trial combining laser interstitial thermal therapy with pembrolizumab immunotherapy showed nearly half of recurrent high-grade astrocytoma patients alive at 18 months, far exceeding typical survival. Separate research reveals steroids make glioblastoma cells vulnerable to dietary interventions targeting their altered metabolism.
The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07615595 |
Dexamethasone to Prevent Side Effects of Spinal Anesthesia in Cesarean Delivery |
ENROLLING_BY_INVITATION | PHASE4 |
| NCT07614802 |
Exparel and Dexamethasone |
NOT_YET_RECRUITING | PHASE4 |
| NCT07614360 |
Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07609706 |
A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment |
NOT_YET_RECRUITING | PHASE1 |
| NCT07608731 |
Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas |
NOT_YET_RECRUITING | PHASE1 |
| NCT07605416 |
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial |
NOT_YET_RECRUITING | PHASE2 |
| NCT07588698 |
Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07584200 |
Comparison of Spinal Anesthesia With Intrathecal Morphine Versus PENG Block With or Without Dexamethasone in Hip Arthroplasty |
NOT_YET_RECRUITING | NA |
| NCT07576660 |
Dexamethasone Treatment for Sepsis-associated Acute Respiratory Distress Syndrome: a Multicenter, Randomised, Double-blinded, Controlled Trial |
NOT_YET_RECRUITING | PHASE3 |
| NCT07570173 |
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) |
RECRUITING | PHASE2/PHASE3 |
